BlackRock’s Audentes Therapeutics, Inc BOLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-3,678,864
| Closed | -$220M | – | 5173 |
|
|
2019
Q4 | $220M | Sell |
3,678,864
-31,951
| -0.9% | -$1.2M | 0.01% | 1416 |
|
|
2019
Q3 | $104M | Buy |
3,710,815
+377,370
| +11% | +$12.9M | ﹤0.01% | 1877 |
|
|
2019
Q2 | $126M | Buy |
3,333,445
+413,768
| +14% | +$15.9M | 0.01% | 1754 |
|
|
2019
Q1 | $114M | Sell |
2,919,677
-54,914
| -2% | -$1.57M | 0.01% | 1787 |
|
|
2018
Q4 | $63.4M | Buy |
2,974,591
+406,605
| +16% | +$10.5M | ﹤0.01% | 2096 |
|
|
2018
Q3 | $102M | Buy |
2,567,986
+109,815
| +4% | +$4.09M | ﹤0.01% | 1959 |
|
|
2018
Q2 | $93.9M | Buy |
2,458,171
+497,767
| +25% | +$18.4M | ﹤0.01% | 1980 |
|
|
2018
Q1 | $58.9M | Buy |
1,960,404
+601,906
| +44% | +$20.4M | ﹤0.01% | 2176 |
|
|
2017
Q4 | $42.5M | Buy |
1,358,498
+158,576
| +13% | +$4.35M | ﹤0.01% | 2388 |
|
|
2017
Q3 | $33.6M | Sell |
1,199,922
-232,866
| -16% | -$5.06M | ﹤0.01% | 2516 |
|
|
2017
Q2 | $27.4M | Buy |
1,432,788
+547,022
| +62% | +$8.74M | ﹤0.01% | 2600 |
|
|
2017
Q1 | $15.1M | Buy |
885,766
+856,397
| +2,916% | +$13.9M | ﹤0.01% | 2920 |
|
|
2016
Q4 | $537K | Buy |
29,369
+214
| +0.7% | +$3.7K | ﹤0.01% | 1682 |
|
|
2016
Q3 | $519K | Buy |
+29,155
| New | +$442K | ﹤0.01% | 1722 |
|
BlackRock's BOLD Position: Q1 2020 in Review
BlackRock sold out of Audentes Therapeutics, Inc (BOLD) in Q1 2020, closing a stake of 3,678,864 shares — an estimated $220M sold.
BlackRock first reported a position in BOLD in Q3 2016 and held it in 14 quarters. The position peaked at $220M in Q4 2019. 0 funds tracked by Wall St. Rank hold BOLD as of Q1 2020.
- BlackRock reported no remaining Audentes Therapeutics, Inc position as of Q1 2020 after selling out during the quarter.
- BlackRock sold 3,678,864 Audentes Therapeutics, Inc shares in Q1 2020, an estimated $220M.
- BlackRock first reported a position in Audentes Therapeutics, Inc in Q3 2016 and held it in 14 quarters.
- BlackRock's Audentes Therapeutics, Inc position peaked at $220M in Q4 2019.
- 0 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q1 2020.
Based on BlackRock's 13F filing for Q1 2020, filed 1 May 2020.